Cosmo Pharmaceuticals Lifts Recurring Revenues, Boosts Dividend and Sets Growth Path to 2030

COSMO Pharmaceuticals N.V. ( (CH:COPN) ) has provided an update.

Cosmo Pharmaceuticals reported 2025 revenue of EUR 104.2 million, with recurring revenues rising 15% to EUR 88.1 million and now accounting for 85% of the total, while EBITDA reached EUR 9.5 million, above guidance despite a small operating loss due to non-recurring 2024 milestones. The company highlighted strong growth from GI Genius and Winlevi, a 6% reduction in operating expenses, a cash and investment position of EUR 128.3 million with no financial debt, a proposed dividend of EUR 2.10 per share, and set 2026 guidance for continued double-digit recurring revenue and EBITDA growth alongside progress on its Vision 2030 targets for a larger, more profitable recurring-revenue base.

For 2026, Cosmo is guiding total revenue of EUR 105–110 million, recurring revenues of EUR 98–102 million, and EBITDA of EUR 10.5–13.5 million, supported by further global expansion of GI Genius and Winlevi and focused R&D in MedTech AI and gastroenterology. Management reiterated mid-term ambitions to grow recurring revenues to around EUR 260 million by 2030, or up to EUR 480 million including pipeline products, with a corresponding increase in EBITDA, underlining the strategic importance of recurring platforms and disciplined capital allocation for shareholders and partners.

The most recent analyst rating on (CH:COPN) stock is a Buy with a CHF134.00 price target. To see the full list of analyst forecasts on COSMO Pharmaceuticals N.V. stock, see the CH:COPN Stock Forecast page.

More about COSMO Pharmaceuticals N.V.

Cosmo Pharmaceuticals N.V. is a specialty pharmaceutical company focused on gastrointestinal disease, dermatology and MedTech AI, with flagship products including the GI Genius AI-powered endoscopy platform and acne treatment Winlevi. The group is shifting its model toward scalable, predictable recurring revenues, underpinned by a debt-free balance sheet and significant cash reserves.

YTD Price Performance: 2.09%

Average Trading Volume: 62,023

Technical Sentiment Signal: Buy

Current Market Cap: CHF1.81B

For a thorough assessment of COPN stock, go to TipRanks’ Stock Analysis page.